The US Food and Drug Administration (USFDA) has conducted an inspection at Alembic Pharmaceuticals
API Facility located at Karkhadi from January 13-17, 2020.
This was a scheduled pre-approval inspection and at the end of the inspection, the USFDA issued a Form 483 with two observations.
On Monday’s trade, Alembic Pharmaceuticals Ltd ended at Rs600, up by Rs1.25 or 0.21% from its previous closing of Rs598.75 on the BSE.
The scrip opened at Rs600 and touched a high and low of Rs600 and Rs600 respectively.